IMPACT OF REMEDSIVER ON OUTCOME OF HOSPITALIZED COVID-19 PATIENTS.

Dheyaa Khalf Al-Omer¹, Dr. Abbas F. Hlaihel², Dr. Majeed Mohan Thajeel Alhamami³, Dr. Ali Abid Saadon⁴

¹University of Thi-Qar- collage of medicine
²University of Thi-Qar collage of medicines
³F. I. B. M. S, Lecturer College of Medicine, University of Thi-Qar
⁴M.B.CH.B M.Sc, Ph.D community physician,
Community medicine department collage of medicine-university of Thi-Qar

I. INTRODUCTION
Corona virus disease 2019 (COVID-19) first pandemic caused by corona virus called SARS-Cov2 which appeared in late 2019 in china caused a cluster cases of pneumonia then spread to more than 200 countries causing great number of cases and significant number of death and shortage in heath care services [1]

Replication novel corona virus [SARS-Cov2] usually lead to many of the clinical manifestations of COVID-19, antiviral therapies are being considered for the treatment of COVID-19.

Mechanisms through which these drugs act including inhibit viral entry, viral membrane fusion and endocytosis, or the activity of the SARS-CoV-2 3-chymotrypsin-like protease (3CLpro) and the RNA-dependent RNA polymerase [2]

The viral replication usually active early in the course of COVID-19, so antiviral therapy may have the greatest role before the illness progresses into the hyperinflammatory state that can characterize the advance stages of disease, including critical illness [3]

Role of antiviral in hospitalized patient with severe or critical COVID-19 are studied and most of them prove that did not show significant benefit in reducing mortality in those patients [4]

Animal models showed that remdesivir has in vivo antiviral activity while lopinavir-ritonavir and hydroxychloroquin doesn't showed the activity [5]

Remdesivir (GS-5734) was discovered by Gilead Sciences is and it is one of therapeutic agents for treating RNA-based viruses that had global potential including EBOV and the Coronaviridae family viruses exemplified by Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS).

Most studies demonstrated that (remdesivir) had a broad activity against RNA viruses, multiple studies studied antiviral activity demonstrating its activity against coronaviruses.

Antiviral activity was confirmed against SARS, MERS zoonotic coronaviruses, as well as the circulating human coronaviruses, causative agents of the common cold

Also de Wit et al. demonstrated that remdesivir had both prophylactic and therapeutic activity against MERS in a nonhuman primate in vivo model. [6]

Remdesivir is an intravenous nucleotide prodrug of an adenosine analog. Remdesivir act through binding to the viral RNA-dependent RNA polymerase, inhibiting viral replication through premature termination of RNA transcription. It has demonstrated in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [7]

Wang et al. studied 237 patients (158 assigned to remdesivir and 79 to placebo) in China early in the pandemic and showed a shorter time to improvement (a two-point improvement) with remdesivir: 21.0 days (95% CI, 13.0 to 28.0) in the remdesivir group and 23.0 days (95% CI, 15.0 to 28.0) in the placebo group (hazard ratio for clinical improvement, 1.23; 95% CI, 0.87 to 1.75). [8] John H. Beigel e tal trial data showed that remdesivir was superior
to placebo in shortening the time to recovery in hospitalized patients with Covid-19 and had evidence of pneumonia [9]

II. PATIENTS AND METHODS

Retrospective analytic study involve 204 patients admitted to Al-Hussein teaching hospital [isolated centre in Al-Nassirya city centre of thi-qar province diagnosed by CT-chest with or without PCR 102 of them received Remdisivir and 102 not receiving any antiviral therapy

Age, sex, co-morbid disease and severity for both group are recorded

Both group received corticosteroid, antibiotic and heparin and other medical all of them are recorded

The outcome of hospitalized patients are assessed by duration of hospitalization, need for RCU and discharge well or death

Those received remdisivire are taken then for five day

200 mg on day 1 then 100 for another 4 days

III. RESULTS

This study involve 204 hospitalized patients with COVID-19 prove by CT scan of the chest ans or PCR [102 patients received remdisivir in addition to other medication and 102 patients not received ant antiviral therapy]

| Table 1: Distribution according to age and duration of disease |
|------------------|-------|-------|-------|----------|-------|------|
| Age              | N     | Mean  | Std. Deviation | ANOVA   | F     | Sig. |
| Remdesvir        | 102   | 52.08 | 9.415           | Between Groups | 6.984 | .009 |
| None             | 102   | 55.44 | 8.747           |          |       |      |
| Total            | 204   | 53.76 | 9.220           |          |       |      |
| Duration         | N     | Mean  | Std. Deviation | ANOVA   | F     | Sig. |
| Remdesvir        | 102   | 10.90 | 3.446           | Between Groups | .976  | .324 |
| None             | 102   | 11.36 | 3.211           |          |       |      |
| Total            | 204   | 11.13 | 3.330           |          |       |      |

In this study the mean age of those received remdesivir is 52.08 while the mean those not received remdesivir is 55.44 with significant difference p value 0.009

The mean duration of hospitalization for those taking remdesivir is 10.90 while duration of hospitalization for non remdesivir is 11.36 with non significant difference p value 0.324
In this study there is 104 male [54 received remdesivir and 54 not received remdesivir] 92 female [48 received remdesivir and 48 not receiving remdesivir] with slight male predominant and there is no difference in sex ratio between two groups.

There no significant difference regarding the severity of disease between two group p value 0.085.

Figure 1: Distribution according to severity of the cases

Fischer exact test=4.764 P value=0.085

There no significant difference regarding the severity of disease between two group p value 0.085.
In this study there no significant difference between remdesivir and non remdesivir regarding the presence of co-morbid disease with p value 0.126

There is no significant difference between remdesivir and non-remdesivir groups regarding the number of medication other than that specific for COVID-19 e.g anti diabetic , anti emetics and others with P value 0.197

There is non significance difference regarding the need for ICU admission between remdesivir and non-remdesivir groups p value 0.868
Most of patients hospitalized with COVID-19 received two antibiotics but 10 patients of remdesivir received three antibiotics with significant difference p value 0.

Chi-square = 8.011, p = 0.004

X² = 10.515  P value = 0.001
### Table 3: Final outcome of the comparative groups

<table>
<thead>
<tr>
<th></th>
<th>Remdesivir</th>
<th>No</th>
<th>Total</th>
<th>X2, P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Well</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>8</td>
<td>17</td>
<td>0.64</td>
</tr>
<tr>
<td></td>
<td>52.9%</td>
<td>47.1%</td>
<td>100.0%</td>
<td>0.800</td>
</tr>
<tr>
<td></td>
<td>93</td>
<td>94</td>
<td>187</td>
<td></td>
</tr>
<tr>
<td></td>
<td>49.7%</td>
<td>50.3%</td>
<td>100.0%</td>
<td></td>
</tr>
<tr>
<td><strong>Death</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>93</td>
<td>94</td>
<td>187</td>
<td></td>
</tr>
<tr>
<td></td>
<td>49.7%</td>
<td>50.3%</td>
<td>100.0%</td>
<td>0.64</td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>8</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td></td>
<td>52.9%</td>
<td>47.1%</td>
<td>100.0%</td>
<td>0.800</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>Count</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>102</td>
<td>102</td>
<td>204</td>
<td></td>
</tr>
<tr>
<td></td>
<td>50.0%</td>
<td>50.0%</td>
<td>100.0%</td>
<td></td>
</tr>
</tbody>
</table>

In this study 93 patients received remdesivir discharge well and 94 patients with remdesivir discharge well with no significant difference p value 0.800

In this study there is 9 patients dead received remedsvir and 8 patients not received remdesivir are dead with no significant difference p value 0.800

There is no significant difference between two groups regarding discharge well or not from hospital with p value 0.800

In this study death rate is the nearly [9:8] with no significant difference p value 0.800

**IV. DISCUSSION**

In this study the mean age of those received remdesivir is 52.08 while the mean those not received remdesivir is 55.44 with significant difference p value 0.009 this can be explained that most of physicians working in COVID-19 afraid of side effects of remdesivir in elderly and used it with caution.

In our study we found that intravenous remdesivir did not significantly improve the time to clinical improvement and duration of hospitalization

The mean duration of hospitalization for those taking remdesivir is 10.90 while duration of hospitalization for non remdesivir is 11.36 with non significant difference p value 0.324. Although this difference not statistically significant, patients receiving remdesivir had a less time to clinical improvement than those not receiving the drug [10.9 to 11]. this go with Yaming etal study that showed no significant difference time in clinical improvement but those received remdesivir are faster time to recover [21 to 23] [10]

John H. Beigel trial showed that patients in the remdesivir group had a shorter time to recovery than patients in the placebo group (median, 10 days, as compared with 15 days; rate ratio for recovery, 1.29; 95% confidence interval [CI], 1.12 to 1.49; P<0.001), although in his trial duration of treatment with remdesivir extend 10 days [11]

In this study the ratio of male to female is the same in patient received remdesivir and those not received remdesivir with non significant difference but in each group male more in than female [54:48 respectively] last global report shows no gender difference in patients although previous report showed slight male predominate [12]
In this study there is no significant difference in severity of disease in patients with remdesivir and those not receiving remdesivir.

In this study there was no significant difference between remdesivir and non-remdesivir regarding the number of comorbid diseases with p value 0.126.

In this study there was no significant difference between remdesivir and non-remdesivir groups regarding the number of medication other than that specific for COVID-19 e.g. anti diabetic, anti emetics and others with p value 0.197.

In this study there is no significance difference regarding the need for ICU admission between remdesivir and non-remdesivir groups p value 0.868.

There is significant number of patients with remdesivir received high dose corticosteroid [20 to 7] with p value 0.004.

There was no evidence suggesting that a higher dose of corticosteroids was associated with greater benefit than a lower dose of corticosteroids.[13]

In this study there is no significant difference between two groups regarding discharge well or not from hospital with p value 0.800.

In this study there is 9 patients dead received remdesivir and 8 patients not received remdesivir are dead with no significant difference p value 0.800.

There was no statistically significant difference in mortality by Day 29 between the remdesivir (11.4%) and placebo (15.2%) arms (HR 0.73; 95% CI, 0.52-1.03; P = 0.07). in The Adaptive COVID-19 Treatment Trial (ACTT-1)[14].

John H. Beigel et al. study The 28-day mortality was similar for the two study arms (14% of participants in the remdesivir arm vs. 13% in the placebo arm).[11]

In the WHO Solidarity Trial death occurred in 301 of 2743 patients receiving remdesivir and in 303 of 2708 receiving its control (rate ratio, 0.95; 95% confidence interval [CI], 0.81 to 1.11; P=0.50)[15] while Pasquini et al. retrospective, observational study showed significantly lower mortality in patients treated with remdesivir (56% vs 92%, P<0.001[16].

Goldman JD, Lye DCB, Hui DS, et al. A study showed hospitalized patients with severe COVID-19 who were not on mechanical ventilation or ECMO, remdesivir treatment for 5 or 10 days had similar clinical benefit.[17]

REFERENCES


www.turkjphysiotherrehabil.org 4493
Yaming Wang et al: Remdesivir in adult with severe COVID-19: a randomized, double . multicentre trial, LANCET volume 385, issue 10236, P1578, May 16, 2020 Trial101


12. Sex, gender and COVID-19 project: global health 5050: African population and health research centre


